share_log

6-K: Gsk on track to deliver 2024 outlooks with further good progress made in r&d

6-K: Gsk on track to deliver 2024 outlooks with further good progress made in r&d

6-K：葛蘭素史克有望實現2024年願景，研發方面取得進一步良好進展
美股SEC公告 ·  2024/10/30 23:27

Moomoo AI 已提取核心訊息

GSK reported Q3 2024 total sales of £8.0 billion, down 2% AER but up 2% CER, driven by strong Specialty Medicines performance offsetting lower Vaccines sales. Core operating profit grew 5% CER to £2.8 billion, reflecting favorable product mix and cost management.Total operating profit fell 86% to £189 million after a £1.8 billion charge for Zantac settlement, covering 93% of US state court cases. Core EPS increased 5% CER to 49.7p, while reported EPS was -1.4p. The company reached agreements to resolve approximately 80,000 Zantac cases for up to $2.2 billion.GSK confirmed its full-year 2024 guidance, expecting to deliver around the middle of ranges: 7-9% sales growth, 11-13% core operating profit growth, and 10-12% core EPS growth at CER. Q3 dividend of 15p declared, with full-year dividend expected at 60p. The company made further R&D progress with 11 positive phase III trials reported year-to-date.
GSK reported Q3 2024 total sales of £8.0 billion, down 2% AER but up 2% CER, driven by strong Specialty Medicines performance offsetting lower Vaccines sales. Core operating profit grew 5% CER to £2.8 billion, reflecting favorable product mix and cost management.Total operating profit fell 86% to £189 million after a £1.8 billion charge for Zantac settlement, covering 93% of US state court cases. Core EPS increased 5% CER to 49.7p, while reported EPS was -1.4p. The company reached agreements to resolve approximately 80,000 Zantac cases for up to $2.2 billion.GSK confirmed its full-year 2024 guidance, expecting to deliver around the middle of ranges: 7-9% sales growth, 11-13% core operating profit growth, and 10-12% core EPS growth at CER. Q3 dividend of 15p declared, with full-year dividend expected at 60p. The company made further R&D progress with 11 positive phase III trials reported year-to-date.
GSk報告2024年第三季的總銷售額爲80億英鎊，按實際匯率下降2%，但按固定匯率上漲2%，這得益於強勁的特殊藥品表現，抵消了疫苗銷售的下降。核心營業利潤按固定匯率增長5%，達到28億英鎊，反映出有利的產品組合和成本管理。由於18億英鎊的Zantac和解費用，導致總營業利潤下降86%，降至18900萬英鎊，覆蓋93%的美國州法院案件。核心每股收益按固定匯率增長5%，至49.7便士，而報告的每股收益爲-1.4便士。公司達成協議解決大約80,000個Zantac案件，金額高達22億美金。GSk確認其2024財年的全年指導，預計將交付大約在範圍中間的業績：銷售增長7-9%，核心營業利潤增長11-13%，核心每股收益按固定匯率增長10-12%。宣佈第三季度股息爲15便士，全年股息預計爲60便士。公司在研發方面進一步取得進展，年初至今報告了11項積極的三期臨牀試驗。
GSk報告2024年第三季的總銷售額爲80億英鎊，按實際匯率下降2%，但按固定匯率上漲2%，這得益於強勁的特殊藥品表現，抵消了疫苗銷售的下降。核心營業利潤按固定匯率增長5%，達到28億英鎊，反映出有利的產品組合和成本管理。由於18億英鎊的Zantac和解費用，導致總營業利潤下降86%，降至18900萬英鎊，覆蓋93%的美國州法院案件。核心每股收益按固定匯率增長5%，至49.7便士，而報告的每股收益爲-1.4便士。公司達成協議解決大約80,000個Zantac案件，金額高達22億美金。GSk確認其2024財年的全年指導，預計將交付大約在範圍中間的業績：銷售增長7-9%，核心營業利潤增長11-13%，核心每股收益按固定匯率增長10-12%。宣佈第三季度股息爲15便士，全年股息預計爲60便士。公司在研發方面進一步取得進展，年初至今報告了11項積極的三期臨牀試驗。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Medicus Pharma
    MDCX
    -- 3.680
    Scilex Holding
    SCLX
    -- 0.354
    阿瑪琳
    AMRN
    -- 0.612
    賽諾菲安萬特
    SNY
    -- 54.500
    艾伯維公司
    ABBV
    -- 192.870
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    科技巨頭財報季如火如荼，英偉達壓軸會表現如何？
    週四， $亞馬遜 (AMZN.US)$ 該公司報告第四季度調整後每股收益爲1.86美元，高於1.50美元的預期，營業收入爲1877.9亿美元，高於1873.2亿美元的預期。公司預測下一季度營收將低於華爾街的預期，預計本季度最多爲1550亿美元，而分析師們希望達到1580亿美元。 展开
    亞馬遜收益預覽：通過猜測開盤價格獲得獎勵！